OncologyEducation presents MedOncNow
OncologyEducation presents MedOncNow
Podcast Description
OncologyEducation, in partnership with Dr. Shaqil Kassam, is proud to present the MedOncNow podcast.
Hosted by Dr. Kassam, MedOncNow offers critical insights on hot topics in medical oncology. From emerging therapies to new standards of care, MedOncNow features discussions with leading oncology experts who share relevant, practical information you can incorporate into your practice.
Podcast Insights
Content Themes
The podcast focuses on critical topics in medical oncology, including emerging therapies, standards of care, and practical treatment discussions. Specific episode examples include a deep dive into treatment options for resectable non-small cell lung cancer (NSCLC) and the second-line treatment of EGFR-positive NSCLC, providing valuable insights into new approaches and clinical trials.
OncologyEducation, in partnership with Dr. Shaqil Kassam, is proud to present the MedOncNow podcast.
Hosted by Dr. Kassam, MedOncNow offers critical insights on hot topics in medical oncology. From emerging therapies to new standards of care, MedOncNow features discussions with leading oncology experts who share relevant, practical information you can incorporate into your practice.
As we now have funded 2nd line access to TDXD (ENHERTU) in the treatment of HER2 + Gastric and GEJ cancer after Trastuzumab containing regimens, Dr. Christine Brezden-Masley takes us through the regimen, its use and efficacy and toxicity management
Disclaimer
This podcast’s information is provided for general reference and was obtained from publicly accessible sources. The Podcast Collaborative neither produces nor verifies the content, accuracy, or suitability of this podcast. Views and opinions belong solely to the podcast creators and guests.
For a complete disclaimer, please see our Full Disclaimer on the archive page. The Podcast Collaborative bears no responsibility for the podcast’s themes, language, or overall content. Listener discretion is advised. Read our Terms of Use and Privacy Policy for more details.